Eli Lilly touches down in Denver during ARVO 2026 vision conference

Eli Lilly and Company's Gulfstream G500, tail number N308EL, departed Kansas City at 4:16 p.m. local time on May 6, slicing through the skies at 45,000 feet before landing at Centennial Airport near Denver just 92 minutes later. The quick hop covered 447 knots at peak speed, a routine jaunt for the pharmaceutical heavyweight's fleet.

The timing aligns neatly with the Association for Research in Vision and Ophthalmology's (ARVO) 2026 Annual Meeting, underway May 3-7 in Denver, where cutting-edge vision science takes the spotlight. Eli Lilly, fresh off acquisitions like Adverum Biotechnologies in October 2025 and a November collaboration with MeiraGTx on gene therapies for retinal diseases, likely sent representatives to network and showcase advancements in this burgeoning field, per announcements on the company's investor site.

This Denver detour follows a flurry of East Coast hops earlier in the week—from Washington and Boston back to Indianapolis headquarters—capping the annual shareholder meeting on May 4, where CEO Dave Ricks highlighted a 45% revenue surge. For a firm chasing GLP-1 dominance while eyeing new frontiers like ophthalmology, such peripatetic flights underscore the relentless pace of big pharma's boardrooms and labs.